Now Available: Liver Fibrosis Models Fed Choline-Deficient, High-Fat Diets

November 26, 2018

If you’re exploring nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) or cancer-associated liver fibrosis, you may want to learn about TD2’s latest murine model: liver fibrosis induced by a choline-deficient, L-amino acid-defined, high-fat diet. The new model is the latest in a series of liver fibrosis animal models TD2 has in its catalogue, that also includes diethylnitrosamine (DEN) and carbon tetrachloride (CCl4) induction models.

The Role of Choline Deficiency

Unlike the chemically induced models, however, the choline-deficient, high-fat diet model replicates dietary habits of a particular subset of patients that can result in pathologic changes in the liver, including fibrosis. In previous studies dating as far back as the 1930s, choline’s ability to remove fat from the liver means a diet lacking the nutrient can activate fibrosis and cancer development.

In the United States, choline sources mainly include meat, poultry, dairy, fish and eggs—plus vegetables such as broccoli and cauliflower, as well as seeds, nuts and whole grains.

Triggering Fibrosis in the Liver

By stripping the animals’ diets of those nutrients and focusing on high-fat foods instead, the animals will in time develop fibrosis. Fibrotic conditions can be highly favorable to liver cancer development, the fifth deadliest cancer in the United States, according to the American Cancer Society. In fact, more than 8 in 10 hepatocellular carcinomas (HCCs) form in livers with fibrosis or cirrhosis.

Given the fact that only 18 percent of liver cancer patients will survive past five years (American Cancer Society), studying medicines to reduce fibrosis using specific animal models isn’t just smart science—it’s crucial.

Practical Applications of a Choline-Deficient Model

TD2’s choline-deficient, high-fat model can be used to study the drug effects on fibrosis using qualitative pathology scoring—as well as to assess a drug’s potential in fibrotic cancers as a surrogate study. Researchers exploring nonalcoholic steatohepatitis (NASH) could also make use of the models’ fibrotic properties.

Those applications all link back to the fact that fibrotic diseases are a widespread health problem. Having access to a diverse model run by an industry, fee-for-service company can help speed development of promising drug candidates.

Given the fact that many cancers are highly fibrotic, fibrosis-reducing drugs can allow for better and more efficient delivery of standard-of-care therapeutics to the tumor. Increased fibrosis can also limit the immune cells from getting to the tumor, reducing the effectiveness of new immunotherapies. Compounds that reduce fibrosis in these experimental models could later be found to significantly improve cancer treatments.

Coming Soon

Check back with TD2 in Q1 2019 for news on a new model of idiopathic pulmonary fibrosis (IPF) that is currently in validation. This model is designed to better recapitulate the human disease and overcome some of the limitations of the current IPF models.

The Significance of Preclinical Evaluation in CAR T-cell Therapy for Solid and Hematologic Tumors

January 30, 2024

Cell therapy has emerged as a promising approach in the field of cancer treatment, and chimeric antigen receptor (CAR) T-cell therapy has shown ...

Read more +

Advancing Preclinical Cancer Research Through Metabolomics: Key Strategies for Biomarker Identification and Drug-Target Analysis in Immuno-Oncology

January 18, 2024

The dynamic field of cancer research is continually evolving, driven by the pursuit of deeper understanding and novel therapeutic strategies against ...

Read more +

Orthotopic vs. Subcutaneous: Unpacking the Strengths and Limitations of Tumor Model Implantation Sites

October 24, 2023

The scientific community has long appreciated the importance of in vivo tumor models for understanding cancer biology and testing therapeutic ...

Read more +

Unveiling the Potential: 5 Ways DIO Mice Enhance Immuno-Oncology Discoveries

August 22, 2023

In the sphere of immuno-oncology research, a powerful tool has emerged - the Diet-Induced Obesity (DIO) mouse model. These models provide researchers ...

Read more +

Get Started

Contact Us Today!

If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.